Login to Your Account



Study: Recording Collaboration Revenue Sticky Spot for Biotech

By Jennifer Boggs


Thursday, October 16, 2008
Recognizing collaboration revenue has never been as easy as it sounds - that impressive $100 million up-front payment, for instance, actually might be amortized over the life of the partnership. But increased SEC scrutiny on collaboration revenue, combined with the growing complexity of biotech deals, has proved a headache for accounting departments throughout the biotech industry. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription